Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
160 patients around the world
Available in Argentina
All infants that are eligible for this study and for whom the parents/legal
representatives give informed consent will be enrolled in this study. All patients will
receive one cycle of blinatumomab on top of the standard treatment backbone after
induction therapy. Medium risk patients, that respond well to the 1st cycle will be
treated with a 2nd cycle of blinatumomab replacing one chemo course after consolidation
therapy. If they do not respond well enough they will be treated according to the current
treatment standard. Minimal residual disease will be used to determine the response to
blinatumomab. High risk patients will be eligible for allogeneic stem cell
transplantation after the first blinatumomab cycle if they are Minimal Residual Disease
(MRD) negative (defined as < 0.01%). Also medium risk patients with insufficient MRD
response after induction or after the 1st cycle of blinatumomab will be allocated to high
risk treatment and will be eligible for allogeneic stem cell transplantation.